- KR₩128bn
- KR₩258bn
- KR₩172bn
- 30
- 48
- 54
- 40
Annual income statement for CKD Bio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 124,600 | 142,238 | 156,042 | 160,353 | 171,756 |
| Cost of Revenue | |||||
| Gross Profit | 27,864 | 13,306 | 16,790 | 8,013 | 35,942 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 117,246 | 153,967 | 170,882 | 180,505 | 160,802 |
| Operating Profit | 7,354 | -11,728 | -14,839 | -20,153 | 10,954 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 7,059 | -13,358 | -18,590 | -24,197 | 9,216 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 6,207 | -6,577 | -16,703 | -24,193 | 8,701 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 6,207 | -6,577 | -16,703 | -24,193 | 8,701 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 6,207 | -6,577 | -16,703 | -24,193 | 8,701 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1,188 | -1,169 | -3,043 | -4,431 | 1,584 |
| Dividends per Share |